Rakovina Therapeutics Inc V.RKV

Alternate Symbol(s): RKVTF

Healthcare Biotechnology

Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. It is focused on the development of cancer treatments based on deoxyribonucleic acid (DNA)-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking and Enki platforms. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.

TSXV:RKV - Post by User

Rakovina Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

(42)
•••

Post by bmreedon Sep 18, 2024 8:47pm

82 Views

Post# 36230188

Webinar $RKV Executive Chair Jeffrey Bacha Sep 24 @ 1PM ET

Live Webinar - Rakovina Therapeutics (RKV) w/ Executive Chairman Jeffrey Bacha

Tuesday, September 24th at 1PM ET / 10AM PT

Q&A with Radius Research

Executive Chairman Jeffery Bacha discusses Rakovina's novel low-cost drug development and partnering strategy targeting DNA-damage response inhibitors.

<< Previous

Bullboard Posts

Next >>

Redefining the future of regenerative medicine